ID

34154

Descrizione

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32; ODM derived from: https://clinicaltrials.gov/show/NCT01286233

collegamento

https://clinicaltrials.gov/show/NCT01286233

Keywords

  1. 14/01/19 14/01/19 -
Titolare del copyright

see on clinicaltrials.gov

Caricato su

14 gennaio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Breast Cancer NCT01286233

Eligibility Breast Cancer NCT01286233

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
the patient must have consented to participate and must have signed and dated an appropriate irb-approved consent form that conforms to federal and institutional guidelines for the ma.32.f study before being enrolled.
Descrizione

ID.1

Tipo di dati

boolean

the patient must be female.
Descrizione

ID.2

Tipo di dati

boolean

the patient must reside in the united states or canada.
Descrizione

ID.3

Tipo di dati

boolean

the patient must be english-speaking.
Descrizione

ID.4

Tipo di dati

boolean

the patient must be eligible for randomization in the ma.32 treatment trial. (participation in the ma.32 qol study is permitted but not required.)
Descrizione

ID.5

Tipo di dati

boolean

the patient must not have started taking ma.32 study therapy.
Descrizione

ID.6

Tipo di dati

boolean

the patient must have completed primary breast radiation therapy at least two weeks prior to enrollment in ma.32.f.
Descrizione

ID.7

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
ma.32 study therapy has been initiated.
Descrizione

ID.8

Tipo di dati

boolean

currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting ma.32 study therapy.
Descrizione

ID.9

Tipo di dati

boolean

Similar models

Eligibility Breast Cancer NCT01286233

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
the patient must have consented to participate and must have signed and dated an appropriate irb-approved consent form that conforms to federal and institutional guidelines for the ma.32.f study before being enrolled.
boolean
ID.2
Item
the patient must be female.
boolean
ID.3
Item
the patient must reside in the united states or canada.
boolean
ID.4
Item
the patient must be english-speaking.
boolean
ID.5
Item
the patient must be eligible for randomization in the ma.32 treatment trial. (participation in the ma.32 qol study is permitted but not required.)
boolean
ID.6
Item
the patient must not have started taking ma.32 study therapy.
boolean
ID.7
Item
the patient must have completed primary breast radiation therapy at least two weeks prior to enrollment in ma.32.f.
boolean
Item Group
C0680251 (UMLS CUI)
ID.8
Item
ma.32 study therapy has been initiated.
boolean
ID.9
Item
currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting ma.32 study therapy.
boolean

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial